BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cassina M, Johnson DL, Robinson LK, Braddock SR, Xu R, Jimenez JL, Mirrasoul N, Salas E, Luo YJ, Jones KL, Chambers CD; for the Organization of Teratology Information Specialists Collaborative Research Group. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis & Rheumatism 2012;64:2085-94. [DOI: 10.1002/art.34419] [Cited by in Crossref: 88] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Bérard A, Sheehy O. The Quebec Pregnancy Cohort--prevalence of medication use during gestation and pregnancy outcomes. PLoS One 2014;9:e93870. [PMID: 24705674 DOI: 10.1371/journal.pone.0093870] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 8.3] [Reference Citation Analysis]
2 Sartori A, Carle D, Freedman MS. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opin Pharmacother 2014;15:1019-27. [PMID: 24742277 DOI: 10.1517/14656566.2014.902936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
3 Chambers C, Johnson DL, Kiernan E. Approach to evaluating pregnancy safety of anti-rheumatic medications in the OTIS MotherToBaby pregnancy studies: what have we learned? Rheumatology (Oxford) 2018;57:v34-9. [PMID: 30137588 DOI: 10.1093/rheumatology/key081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lateef A, Petri M. Systemic Lupus Erythematosus and Pregnancy. Rheum Dis Clin North Am 2017;43:215-26. [PMID: 28390564 DOI: 10.1016/j.rdc.2016.12.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
5 Andersen JB, Moberg JY, Spelman T, Magyari M. Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study. Front Immunol 2018;9:2706. [PMID: 30532753 DOI: 10.3389/fimmu.2018.02706] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
6 Harville EW, Mishra GD, Yeung E, Mumford SL, Schisterman EF, Jukic AM, Hatch EE, Mikkelsen EM, Jiang H, Ehrenthal DB, Porucznik CA, Stanford JB, Wen SW, Harvey A, Symons Downs D, Yajnik C, Santillan D, Santillan M, McElrath TF, Woo JG, Urbina EM, Chavarro JE, Sotres-Alvarez D, Bazzano L, Zhang J, Steiner A, Gunderson EP, Wise LA. The Preconception Period analysis of Risks and Exposures Influencing health and Development (PrePARED) consortium. Paediatr Perinat Epidemiol 2019;33:490-502. [PMID: 31659792 DOI: 10.1111/ppe.12592] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Varytė G, Zakarevičienė J, Ramašauskaitė D, Laužikienė D, Arlauskienė A. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity. Medicina (Kaunas) 2020;56:E49. [PMID: 31973138 DOI: 10.3390/medicina56020049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Oh J, O’connor PW. Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs 2013;27:591-609. [DOI: 10.1007/s40263-013-0080-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
9 Fattah A, Asadi A, Shayesteh MRH, Hesari FH, Jamalzehi S, Abbasi M, Mousavi MJ, Aslani S. Fertility and infertility implications in rheumatoid arthritis; state of the art. Inflamm Res 2020;69:721-9. [PMID: 32458007 DOI: 10.1007/s00011-020-01362-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Moroni G, Ponticelli C. Important considerations in pregnant patients with lupus nephritis. Expert Rev Clin Immunol 2018;14:489-98. [PMID: 29764231 DOI: 10.1080/1744666X.2018.1476139] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Ying S, Xiaomeng C, Xiaomin D, Jiang L, Peng L, Lili M, Rongyi C, Zongfei J, Huiyong C, Lindi J. Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Ther Adv Musculoskelet Dis 2020;12:1759720X20930114. [PMID: 32536986 DOI: 10.1177/1759720X20930114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Fragoso YD, Brooks JB. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol 2015;8:315-20. [PMID: 25712857 DOI: 10.1586/17512433.2015.1019343] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
13 Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS, Le Guillou AC, Yakoub-Agha I, Dharancy S, Noel C, Vantyghem MC. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 2015;10:136. [PMID: 26490561 DOI: 10.1186/s13023-015-0332-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 14.0] [Reference Citation Analysis]
14 Oh J, O'Connor PW. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 2014;7:239-52. [PMID: 25342978 DOI: 10.1177/1756285614546855] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
15 Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 2016;19:834-43. [PMID: 27125255 DOI: 10.1111/1756-185X.12860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Friedman JM. Editorial In Bed with The Devil: Recognizing Human Teratogenic Exposures. Birth Defects Res 2017;109:1407-13. [PMID: 29152923 DOI: 10.1002/bdr2.1134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Moroni G, Ponticelli C. Pregnancy in women with systemic lupus erythematosus (SLE). European Journal of Internal Medicine 2016;32:7-12. [DOI: 10.1016/j.ejim.2016.04.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 6.2] [Reference Citation Analysis]
18 Moyer A, Chakravarty EF. Management of Pregnancy in Lupus. Rheum Dis Clin North Am 2021;47:441-55. [PMID: 34215373 DOI: 10.1016/j.rdc.2021.04.008] [Reference Citation Analysis]
19 McCoyd M. Update on therapeutic options for multiple sclerosis. Neurol Clin 2013;31:827-45. [PMID: 23896508 DOI: 10.1016/j.ncl.2013.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Kattah AG, Garovic VD. Pregnancy and Lupus Nephritis. Semin Nephrol 2015;35:487-99. [PMID: 26573551 DOI: 10.1016/j.semnephrol.2015.08.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
21 Bérard A, Zhao J, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis 2018;77:500-9. [DOI: 10.1136/annrheumdis-2017-212078] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
22 Weber-schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, Johnson D, Cuppers-maarschalkerweerd B, Pistelli A, Clementi M, Winterfeld U, Eleftheriou G, Pupco A, Kao K, Malm H, Elefant E, Koren G, Vial T, Ornoy A, Meister R, Schaefer C; on behalf of the Network of French Pharmacovigilance Centers. Pregnancy Outcome After Methotrexate Treatment for Rheumatic Disease Prior to or During Early Pregnancy: A Prospective Multicenter Cohort Study: MTX Treatment and Pregnancy Outcome. Arthritis & Rheumatology 2014;66:1101-10. [DOI: 10.1002/art.38368] [Cited by in Crossref: 97] [Cited by in F6Publishing: 78] [Article Influence: 13.9] [Reference Citation Analysis]
23 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
24 Sachs C, Tebacher-Alt M, Mark M, Cribier B, Lipsker D. [Aplasia cutis congenita and antithyroid drugs during pregnancy: Case series and literature review]. Ann Dermatol Venereol. 2016;143:423-435. [PMID: 27033749 DOI: 10.1016/j.annder.2016.02.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
25 Sammaritano LR, Bermas BL. Management of pregnancy and lactation. Best Practice & Research Clinical Rheumatology 2018;32:750-66. [DOI: 10.1016/j.berh.2019.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Weber-schoendorfer C, Beck E, Tissen-diabaté T, Schaefer C. Leflunomide – A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reproductive Toxicology 2017;71:101-7. [DOI: 10.1016/j.reprotox.2017.04.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
27 Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Current Opinion in Rheumatology 2014;26:334-40. [DOI: 10.1097/bor.0000000000000054] [Cited by in Crossref: 48] [Cited by in F6Publishing: 11] [Article Influence: 6.9] [Reference Citation Analysis]
28 Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther 2014;3:133-8. [PMID: 26000229 DOI: 10.1007/s40120-014-0020-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
29 Puchner A, Gröchenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, Högenauer C, Koch R, Hermann J, Studnicka-Benke A, Weger W, Puchner R, Dejaco C. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.Wien Klin Wochenschr. 2019;131:29-44. [PMID: 30643992 DOI: 10.1007/s00508-019-1448-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
30 Ponticelli C, Moroni G. Immunosuppression in pregnant women with systemic lupus erythematosus. Expert Rev Clin Immunol 2015;11:549-52. [PMID: 25842985 DOI: 10.1586/1744666X.2015.1033404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
31 Bandoli G, Palmsten K, Chambers C. Acetaminophen use in pregnancy: Examining prevalence, timing, and indication of use in a prospective birth cohort. Paediatr Perinat Epidemiol 2020;34:237-46. [PMID: 31696962 DOI: 10.1111/ppe.12595] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
32 Zhang J, Curtis JR. Considerations in using registry and health plan data for studying pregnancy in rheumatic diseases. Curr Opin Rheumatol 2014;26:315-20. [PMID: 24667289 DOI: 10.1097/BOR.0000000000000056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
33 Balbi GGM, Domingues V, Balbi GGM, De Jesús GR, Levy RA. Use of synthetic and biologic DMARDs during pregnancy. Expert Rev Clin Immunol 2019;15:27-39. [PMID: 30365902 DOI: 10.1080/1744666X.2019.1541739] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 2016;15:955-63. [PMID: 27490204 DOI: 10.1016/j.autrev.2016.07.014] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
35 Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opinion on Drug Safety 2014;13:1591-9. [DOI: 10.1517/14740338.2014.951326] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
36 Wiese MD, Rowland A, Polasek TM, Sorich MJ, O'doherty C. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism & Toxicology 2013;9:1025-35. [DOI: 10.1517/17425255.2013.800483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
37 Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014;74:659-74. [PMID: 24740824 DOI: 10.1007/s40265-014-0212-x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 25.5] [Reference Citation Analysis]
38 Sammaritano LR. Pregnancy in rheumatic disease patients. J Clin Rheumatol 2013;19:259-66. [PMID: 23884185 DOI: 10.1097/RHU.0b013e31829ce35f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
39 Kim SC, Hernandez-Diaz S. Editorial: Safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases. Arthritis Rheumatol. 2014;66:246-249. [PMID: 24504795 DOI: 10.1002/art.38258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
40 Saavedra Salinas MÁ, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-salinas CA, Álvarez Nemegyei J, Fraga Mouret A, Orozco Alcalá J, Salazar Páramo M, Cruz Reyes CV, Andrade Ortega L, Vera Lastra OL, Mendoza Pinto C, Sánchez González A, Cruz Cruz PDR, Morales Hernández S, Portela Hernández M, Pérez Cristóbal M, Medina García G, Hernández Romero N, Velarde Ochoa MDC, Navarro Zarza JE, Portillo Díaz V, Vargas Guerrero A, Goycochea Robles MV, García Figueroa JL, Barreira Mercado E, Amigo Castañeda MC. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. Reumatología Clínica 2015;11:305-15. [DOI: 10.1016/j.reuma.2014.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
41 Cardiel MH, Díaz-Borjón A, Vázquez del Mercado Espinosa M, Gámez-Nava JI, Barile Fabris LA, Pacheco Tena C, Silveira Torre LH, Pascual Ramos V, Goycochea Robles MV, Aguilar Arreola JE, González Díaz V, Alvarez Nemegyei J, González-López Ldel C, Salazar Páramo M, Portela Hernández M, Castro Colín Z, Xibillé Friedman DX, Alvarez Hernández E, Casasola Vargas J, Cortés Hernández M, Flores-Alvarado DE, Martínez Martínez LA, Vega-Morales D, Flores-Suárez LF, Medrano Ramírez G, Barrera Cruz A, García González A, López López SM, Rosete Reyes A, Espinosa Morales R; Mexican College of Rheumatology. Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis. Reumatol Clin 2014;10:227-40. [PMID: 24333119 DOI: 10.1016/j.reuma.2013.10.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
42 Hammad I, Porter TF. An Update on Biologic Agents During Pregnancy. Clin Perinatol. 2020;47:733-742. [PMID: 33153658 DOI: 10.1016/j.clp.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Kaplan TB. Management of Demyelinating Disorders in Pregnancy. Neurol Clin 2019;37:17-30. [PMID: 30470273 DOI: 10.1016/j.ncl.2018.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
44 Østensen M, Förger F. How safe are anti-rheumatic drugs during pregnancy? Current Opinion in Pharmacology 2013;13:470-5. [DOI: 10.1016/j.coph.2013.03.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
45 Lateef A, Petri M. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 2013;27:435-47. [PMID: 24238698 DOI: 10.1016/j.berh.2013.07.005] [Cited by in Crossref: 89] [Cited by in F6Publishing: 66] [Article Influence: 12.7] [Reference Citation Analysis]
46 Coyle PK. Multiple sclerosis in pregnancy. Continuum (Minneap Minn) 2014;20:42-59. [PMID: 24492810 DOI: 10.1212/01.CON.0000443836.18131.c9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
47 Cassina M, Cagnoli GA, Zuccarello D, Di Gianantonio E, Clementi M. Human teratogens and genetic phenocopies. Understanding pathogenesis through human genes mutation. Eur J Med Genet 2017;60:22-31. [PMID: 27639441 DOI: 10.1016/j.ejmg.2016.09.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
48 Soh MC, Nelson-piercy C. High-risk pregnancy and the rheumatologist. Rheumatology 2015;54:572-87. [DOI: 10.1093/rheumatology/keu394] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.9] [Reference Citation Analysis]
49 . ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation. Obstetrics & Gynecology 2019;133:e287-95. [DOI: 10.1097/aog.0000000000003176] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
50 Kurizky PS, Ferreira Cde C, Nogueira LS, Mota LM. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding. An Bras Dermatol 2015;90:367-75. [PMID: 26131868 DOI: 10.1590/abd1806-4841.20153113] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
51 Papadopoulou A, Kappos L, Sprenger T. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety 2015;14:749-59. [DOI: 10.1517/14740338.2015.1014795] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
52 Lateef A, Petri M. Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol. 2012;8:710-718. [PMID: 22907290 DOI: 10.1038/nrrheum.2012.133] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.2] [Reference Citation Analysis]
53 Barbhaiya M, Bermas BL. Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy. Clinical Immunology 2013;149:225-35. [DOI: 10.1016/j.clim.2013.05.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
54 I Keen H, Conaghan PG, Tett SE. Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opinion on Drug Safety 2013;12:581-8. [DOI: 10.1517/14740338.2013.798299] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
55 Krause ML, Makol A. Management of rheumatoid arthritis during pregnancy: challenges and solutions. Open Access Rheumatol 2016;8:23-36. [PMID: 27843367 DOI: 10.2147/OARRR.S85340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
56 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
57 Dai X, Cui X, Sun Y, Ma L, Jiang L. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study. Ther Adv Chronic Dis 2020;11:2040622320922019. [PMID: 32551033 DOI: 10.1177/2040622320922019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
58 Castro-Gutierrez A, Young K, Bermas BL. Pregnancy and Management in Women with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Obstetric Antiphospholipid Syndrome. Med Clin North Am 2021;105:341-53. [PMID: 33589107 DOI: 10.1016/j.mcna.2020.10.002] [Reference Citation Analysis]
59 Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Review of Clinical Immunology 2016;12:937-44. [DOI: 10.1080/1744666x.2016.1184973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
60 Cui X, Dai X, Ma L, Yang C, Tan W, Zhang L, Zhang Z, Feng X, Wu R, Zou Y, Zhou Z, Lu Y, Wang Y, Wu M, Li S, Wang L, Lin H, Dong Z, Fu W, Sun X, Wang C, Ding J, Lv P, Lin J, Jiang L. Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. Seminars in Arthritis and Rheumatism 2020;50:59-65. [DOI: 10.1016/j.semarthrit.2019.06.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
61 Pfaller B, Pupco A, Leibson T, Aletaha D, Ito S. A critical review of the reproductive safety of Leflunomide. Clin Rheumatol 2020;39:607-12. [DOI: 10.1007/s10067-019-04819-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
62 Bazzani C, Andreoli L, Agosti M, Nalli C, Tincani A. Antirheumatic drugs and reproduction in women and men with chronic arthritis. RMD Open 2015;1:e000048. [PMID: 26557371 DOI: 10.1136/rmdopen-2015-000048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
63 Peterson EA, Lynton J, Bernard A, Santillan MK, Bettendorf B. Rheumatologic Medication Use During Pregnancy. Obstet Gynecol 2020;135:1161-76. [PMID: 32282595 DOI: 10.1097/AOG.0000000000003755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Henson LJ, Afsar S, Davenport L, Purvis A, Poole EM, Truffinet P. Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. Reprod Toxicol 2020;95:45-50. [PMID: 32407881 DOI: 10.1016/j.reprotox.2020.04.073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Oh J, O'Connor PW. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag 2013;9:177-90. [PMID: 23761970 DOI: 10.2147/TCRM.S30947] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
66 Giles I, Yee C, Gordon C. Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol 2019;15:391-402. [DOI: 10.1038/s41584-019-0240-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]